Reshma Rangwala - 24 Jan 2022 Form 4 Insider Report for Aravive, Inc.

Role
Chief Medical Officer
Signature
/s/ Abel Svitavsky, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
24 Jan 2022
Net transactions value
$0
Form type
4
Filing time
25 Jan 2022, 15:05:28 UTC
Next filing
29 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARAV Stock Option (Right to buy) Award $0 +175,000 $0.000000 175,000 24 Jan 2022 Common Stock 175,000 $2.18 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options vest pro rata on a monthly basis over four (4) years commencing on February 24, 2022, the one-month anniversary of the grant date.